[Shanghai Pharmaceutical: application for listing of Valganciclovir Hydrochloride approved] Xinhua News Agency, May 16, Shanghai Pharmaceutical announcement, Shangyao Kangli, a wholly-owned subsidiary, received a "Application approval notice for Chemical API" issued by the State Drug Administration on valganciclovir hydrochloride, and the drug was approved for production. Valganciclovir hydrochloride is mainly used to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) and to prevent CMV infection in patients with high-risk solid organ transplantation.